Subspecialty	Infectious Disease
Clinical Interests	Infectious Disease
	HIV
	Hepatitis C Virus Infection
Gender	Male
E-mail	daniel.fierer@mssm.edu
Education and Training	MD, Yale University School of Medicine
	Residency, Internal Medicine, University of California, San Diego
	Fellowship, Infectious Diseases, National Institutes of Health
	Fellowship, Infectious Diseases, National Institutes of Health
	Fellowship, Infectious Diseases, University of California Hospitals

Dr. Fierer sees patients in the FPA, 5 East 98th Street, 11th floor, New York, NY 10029 for infectious diseases, specializing in HIV and/or Hepatitus C Virus infection. Most insurance are accepted. Dr. Fierer also sees patients with or at risk for HIV/Aids in the Jack Martin Fund Clinic located in the Center for Ambulatory Medicine, 17 East 102nd Street, 3rd floor, New York, NY 10029. Insurances accepted are Medicaid, Medicare and ADAP.

Education and Training	MD, Yale University School of Medicine
	Residency, Internal Medicine, University of California, San Diego
	Fellowship, Infectious Diseases, National Institutes of Health
	Fellowship, Infectious Diseases, National Institutes of Health
	Fellowship, Infectious Diseases, University of California Hospitals
Board Certification	Infectious Disease

Subspecialty	Infectious Disease
Clinical Interests	Infectious Disease
	HIV
	Hepatitis C Virus Infection
Board Certification	Infectious Disease

Dr. Fierer's research interests are focused on the study of acute hepatitis C (HCV) infection in HIV-infected patients. Hepatitis C infection is highly prevalent in HIV-infected people, but hepatitis C is rarely diagnosed during the acute phase (first 6 months) of infection and so little is known about the early course of hepatitis C infection. Further, people who are already HIV-infected at the time they contract HCV infection may be at particular risk of having significant liver disease: a preliminary study in collaboration with Drs Branch and Dieterich showed the presence of moderately advanced liver damage in HIV-infected people who have acute HCV infection. Dr. Fierer has initiated a larger study to evaluate HIV-infected patients referred by their physicians for acute HCV infection to further investigate the early effects of this infection on liver pathology, on the natural history of the disease, on the effectiveness of treatment, and of the mode of transmission.

Fierer DS, Uriel AJ, Carriero DC, Klepper A, Dieterich DT, Mullen MP, Thung SN, Fiel MI, Branch AD. Liver fibrosis in an outbreak of acute HCV in HIV-infected men: a prospective cohort study. J Infect Dis 2008 September;.

Fierer DS, Vargas J Jr., Patel N, Clover G. Absence of erythrocyte-associated HIV-1 in vivo. J. Infect. Dis 2007; 196: 587-590.

Fierer DS, Klotman ME. Kidney and central nervous system as reservoirs of HIV infection. Curr Opin HIV AIDS 2006; 1: 115-120.

Schwartz EJ, Fierer DS, Neumann AU, Keller MJ, Parkas V, Zhang DY, Klotman ME, Winston JA, Klotman PE. HIV-1 dynamics in haemodialysis patients. AIDS 2002 June; 16(9): 1301-1303.

Kaplan G, Thomas S, Fierer DS, Mulligan K, Hastlett PA, Fessel WJ, Smith LG, Kook KA, Stirling D, Schambelan M. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000 September; 16(14): 1345-1355.

Fierer DS, Challberg MD. The stoichiometry of binding of the herpes simplex virus type 1 origin binding protein, UL9, to OriS. J Biol Chem 1995 March; 270(13): 7330-7334.

Fierer DS, Challberg MD. Purification and characterization of UL9, the herpes simplex virus type 1 origin-binding protein. J Virol 1992 July; 66(7): 3986-3995.